{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:40:43Z","timestamp":1789767643801,"version":"4.0.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.neurol.2022.06.014","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T09:35:53Z","timestamp":1667468153000},"page":"141-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["CSF biomarkers in primary CNS lymphoma"],"prefix":"10.1016","volume":"179","author":[{"given":"L.","family":"Nguyen-Them","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-7639","authenticated-orcid":false,"given":"A.","family":"Alentorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-2289","authenticated-orcid":false,"given":"G.","family":"Ahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Soussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9182-5846","authenticated-orcid":false,"given":"B.","family":"Mathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Le Garff Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2931-7522","authenticated-orcid":false,"given":"C.","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hoang-Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2022.06.014_bib0395","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: an LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.06.014_bib0400","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0405","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/CCO.0000000000000233","article-title":"Recent developments and controversies in primary central nervous system lymphoma","volume":"27","author":"Hottinger","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0410","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.neurol.2020.08.004","article-title":"Cerebrospinal fluid interleukin-10 may be a useful biomarker for atypical primary central nervous system lymphoma relapse","volume":"177","author":"Autier","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2022.06.014_bib0415","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0387-7604(00)00165-0","article-title":"Lyme borreliosis mimicking central nervous system malignancy: the diagnostic pitfall of cerebrospinal fluid cytology","volume":"22","author":"Kieslich","year":"2000","journal-title":"Brain Dev"},{"key":"10.1016\/j.neurol.2022.06.014_bib0420","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ana.410380212","article-title":"Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications","volume":"38","author":"Balmaceda","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0425","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0022-510X(94)90159-7","article-title":"A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid","volume":"121","author":"Dux","year":"1994","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2022.06.014_bib0430","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0435","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.2008.17.7089","article-title":"Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry","volume":"27","author":"Quijano","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0440","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.leukres.2007.12.016","article-title":"Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas","volume":"32","author":"Di Noto","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.neurol.2022.06.014_bib0445","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cyto.b.21001","article-title":"Ten antibodies, six colors, twelve parameters: a multiparameter flow cytometric approach to evaluate leptomeningeal disease in B-cell non-Hodgkin's lymphomas","volume":"82","author":"Stacchini","year":"2012","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.neurol.2022.06.014_bib0450","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology","volume":"105","author":"Hegde","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2022.06.014_bib0455","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1212\/01.wnl.0000326958.52546.f5","article-title":"Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients","volume":"71","author":"Fischer","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.06.014_bib0460","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2006.03.012","article-title":"CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course","volume":"247","author":"Ekstein","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2022.06.014_bib0465","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1212\/WNL.58.3.390","article-title":"CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes","volume":"58","author":"Gleissner","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.06.014_bib0470","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/neuonc\/nop053","article-title":"Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort","volume":"12","author":"Kiewe","year":"2010","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.neurol.2022.06.014_bib0475","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1600-0609.2010.01475.x","article-title":"Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas","volume":"85","author":"Schroers","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0480","first-page":"429","article-title":"The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas","volume":"91","author":"Fischer","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.neurol.2022.06.014_bib0485","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0490","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0495","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/hon.2021","article-title":"Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients","volume":"31","author":"Ghesqui\u00e8res","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0500","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.06.014_bib0505","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1599::AID-CNCR14>3.0.CO;2-J","article-title":"Cerebrospinal fluid lactate dehydrogenase isoenzyme analysis for the diagnosis of central nervous system involvement in hematooncologic patients","volume":"88","author":"Lossos","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.neurol.2022.06.014_bib0510","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0197-0186(93)90004-O","article-title":"Changes in lactate dehydrogenase isoenzyme pattern in patients with tumors of the central nervous system","volume":"22","author":"Subhash","year":"1993","journal-title":"Neurochem Int"},{"key":"10.1016\/j.neurol.2022.06.014_bib0515","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/1097-0142(19830701)52:1<101::AID-CNCR2820520119>3.0.CO;2-Y","article-title":"Detection of central nervous system metastasis with cerebrospinal fluid beta-2-microglobulin","volume":"52","author":"Koch","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.neurol.2022.06.014_bib0520","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/archneur.1987.00520210017012","article-title":"Cerebrospinal fluid immunoglobulins and beta 2-microglobulin in lymphoproliferative and other neoplastic diseases of the central nervous system","volume":"44","author":"Ernerudh","year":"1987","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0525","first-page":"301","article-title":"Cerebrospinal fluid beta-2-microglobulin: a reliable index of leukaemic infiltration of central nervous system","volume":"37","author":"Storti","year":"1986","journal-title":"Scand J Haematol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0530","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1002\/cam4.3048","article-title":"Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and \u03b22-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma","volume":"9","author":"Maeyama","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.neurol.2022.06.014_bib0535","first-page":"631","article-title":"[CSF levels and diagnostic utility of cerebrospinal fluid beta2-microglobulin]","volume":"63","author":"Caudie","year":"2005","journal-title":"Ann Biol Clin (Paris)"},{"key":"10.1016\/j.neurol.2022.06.014_bib0540","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood.V87.5.1985.1985","article-title":"Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies","volume":"87","author":"Kersten","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2022.06.014_bib0545","doi-asserted-by":"crossref","first-page":"495402","DOI":"10.1155\/2014\/495402","article-title":"Beta2-microglobulin as a diagnostic marker in cerebrospinal fluid: a follow-up study","volume":"2014","author":"Svato\u0148ov\u00e1","year":"2014","journal-title":"Dis Markers"},{"key":"10.1016\/j.neurol.2022.06.014_bib0550","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0140-6736(93)92814-A","article-title":"Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system","volume":"342","author":"Cinque","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2022.06.014_bib0555","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.48.3.687","article-title":"Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF","volume":"48","author":"Antinori","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.06.014_bib0560","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1086\/420934","article-title":"Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma","volume":"38","author":"Ivers","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.neurol.2022.06.014_bib0565","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2169\/internalmedicine.52.9088","article-title":"Epstein-Barr viral load in cerebrospinal fluid as a diagnostic marker of central nervous system involvement of AIDS-related lymphoma","volume":"52","author":"Yanagisawa","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.neurol.2022.06.014_bib0570","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.2000.18.19.3325","article-title":"Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas","volume":"18","author":"Cingolani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0575","first-page":"5499","article-title":"Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors","volume":"56","author":"Voorzanger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.neurol.2022.06.014_bib0580","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF03167070","article-title":"Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma","volume":"60","author":"el-Far","year":"2004","journal-title":"J Physiol Biochem"},{"key":"10.1016\/j.neurol.2022.06.014_bib0585","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2141.1994.tb05116.x","article-title":"Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma","volume":"88","author":"Stasi","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0590","first-page":"60","article-title":"Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma","volume":"17","author":"Lech-Maranda","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.neurol.2022.06.014_bib0595","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1167\/iovs.06-0031","article-title":"IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma","volume":"48","author":"Cassoux","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.neurol.2022.06.014_bib0600","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/blood-2013-01-476333","article-title":"CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma","volume":"121","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2022.06.014_bib0605","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.03.080","article-title":"The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients","volume":"61","author":"Nguyen-Them","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neurol.2022.06.014_bib0610","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-014-1622-z","article-title":"Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system","volume":"121","author":"Sasagawa","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0615","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/neuonc\/nor203","article-title":"Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)","volume":"14","author":"Sasayama","year":"2012","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.neurol.2022.06.014_bib0620","doi-asserted-by":"crossref","first-page":"38671","DOI":"10.1038\/srep38671","article-title":"Cerebrospinal Fluid IL-10 and IL-10\/IL-6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma","volume":"6","author":"Song","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2022.06.014_bib0625","first-page":"2","article-title":"Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma","volume":"21","author":"Geng","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.neurol.2022.06.014_bib0630","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.2147\/CMAR.S255482","article-title":"High Level of IL-10 in cerebrospinal fluid is specific for diagnosis of primary central nervous system lymphoma","volume":"12","author":"Shao","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.neurol.2022.06.014_bib0635","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3174\/ajnr.A4450","article-title":"The Combined Performance of ADC, CSF CXC chemokine ligand 13, and CSF interleukin 10 in the diagnosis of central nervous system lymphoma","volume":"37","author":"Mabray","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0640","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2002-05-1576","article-title":"Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma","volume":"101","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2022.06.014_bib0645","first-page":"654543","article-title":"CXCL13 and CXCL9 CSF levels in central nervous system lymphoma-diagnostic","volume":"12","author":"Masouris","year":"2021","journal-title":"Therapeutic, and Prognostic Relevance. Front Neurol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0650","first-page":"21","article-title":"Chemokine Ligand 13 (CXCL13) in neuroborreliosis and neurosyphilis as selected spirochetal neurological diseases: a review of its diagnostic significance","author":"Gudowska-Sawczuk","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurol.2022.06.014_bib0655","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2013-11-537993","article-title":"Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome","volume":"123","author":"Mu\u00f1iz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2022.06.014_bib0660","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF02849967","article-title":"Levels of serum and cerebrospinal fluid soluble CD27 in the diagnosis of leptomeningeal involvement of hematolymphoid malignancies","volume":"24","author":"Kara","year":"2007","journal-title":"Adv Ther"},{"key":"10.1016\/j.neurol.2022.06.014_bib0665","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/01616412.2000.11740697","article-title":"Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients","volume":"22","author":"Murase","year":"2000","journal-title":"Neurol Res"},{"key":"10.1016\/j.neurol.2022.06.014_bib0670","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1471-2407-7-185","article-title":"Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study","volume":"7","author":"Hildebrandt","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neurol.2022.06.014_bib0675","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2007.12.1053","article-title":"Protein biomarker identification in the CSF of patients with CNS lymphoma","volume":"26","author":"Roy","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0680","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00277-015-2334-y","article-title":"Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma","volume":"94","author":"Kuusisto","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0685","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/neuonc\/nov092","article-title":"CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma","volume":"17","author":"Viaccoz","year":"2015","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.neurol.2022.06.014_bib0690","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1002\/cam4.1581","article-title":"The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma","volume":"7","author":"Geng","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.neurol.2022.06.014_bib0695","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"Gonzalez-Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurol.2022.06.014_bib0700","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","article-title":"Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma","volume":"122","author":"Montesinos-Rongen","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0705","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bjh.13078","article-title":"MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome","volume":"167","author":"Poulain","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0710","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/hon.2489","article-title":"The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid","volume":"36","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0715","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40478-019-0692-8","article-title":"Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis","volume":"7","author":"Rimelen","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurol.2022.06.014_bib0720","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2015-01-620518","article-title":"High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates","volume":"126","author":"Bonzheim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2022.06.014_bib0725","first-page":"1","article-title":"High detection rate of MYD88 mutations in cerebrospinal fluid from patients with CNS lymphomas","author":"Watanabe","year":"2019","journal-title":"JCO Prec Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0730","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.17357","article-title":"MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study","volume":"193","author":"Ferreri","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0735","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrg2634","article-title":"Causes and consequences of microRNA dysregulation in cancer","volume":"10","author":"Croce","year":"2009","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.neurol.2022.06.014_bib0740","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0745","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood-2010-09-308684","article-title":"Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system","volume":"117","author":"Baraniskin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2022.06.014_bib0750","first-page":"11","author":"Zajdel","year":"2019","journal-title":"Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas. Cancers (Basel)"},{"key":"10.1016\/j.neurol.2022.06.014_bib0755","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/neuonc\/nov144","article-title":"Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma","volume":"18","author":"Baraniskin","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0760","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ajh.25578","article-title":"Optimization of CSF biological investigations for CNS lymphoma diagnosis","volume":"94","author":"Armand","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neurol.2022.06.014_bib0765","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z","article-title":"Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results","volume":"82","author":"Glantz","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.neurol.2022.06.014_bib0770","series-title":"More than ever - The importance of CSF analysis for diagnosis of CNS lymphoma","author":"Ahle","year":"2017"},{"key":"10.1016\/j.neurol.2022.06.014_bib0775","first-page":"111","volume":"8","author":"Engelborghs","year":"2017","journal-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst)"},{"key":"10.1016\/j.neurol.2022.06.014_bib0780","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cyto.b.21097","article-title":"Use of TransFix\u2122 cerebrospinal fluid storage tubes prevents cellular loss and enhances flow cytometric detection of malignant hematological cells after 18hours of storage","volume":"86","author":"de Jongste","year":"2014","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:46:39Z","timestamp":1758519999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722007846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0035378722007846"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.06.014","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CSF biomarkers in primary CNS lymphoma","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}